Together, our findings suggest impaired ketogenesis and dysregulated hepatic Hmgcs2 expression as possible markers of NAFLD progression and susceptibility, highlighting a possible role of controlled ketogenic activation as a potential therapy for hepatosteatosis. The gene discussed is HMGCS2; the disease is metabolic dysfunction-associated steatotic liver disease.